Rat VEGF Antibody Summary
Ala27-Arg190
Accession # AAL07526
Complete Your Research
Complete Your Experiment
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data

VEGF164in Rat Kidney. VEGF164was detected in perfusion fixed frozen sections of rat kidney using 15 µg/mL Goat Anti-Rat VEGF164Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

Cell Proliferation Induced by VEGF164and Neutralization by Rat VEGF Antibody. Recombinant Rat VEGF164(Catalog # 564-RV) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Rat VEGF164(20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Rat VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564). The ND50 is typically 0.2-0.6 µg/mL.

Detection of Recombinant Rat and Mouse VEGF by Western Blot. Western blot shows 25 ng of Recombinant Rat VEGF 164 (Catalog # 564-RV), Recombinant Human VEGF 165 (Catalog # 293-VE) and Recombinant Mouse VEGF 164 (Catalog # 493-MV). PVDF Membrane was probed with 0.1 µg/mL of Goat Anti-Rat VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for VEGF at approximately 20-25 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.This antibody does not detect natural VEGF in lysates from cell lines or tissues.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: VEGF
Vascular Endothelial Growth Factor (VEGF or VEGF-A), also known as Vascular Permeability Factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure. VEGF164 appears to be the most abundant and potent isoform, followed by VEGF120 and VEGF188. Rat VEGF164 is an approximately 25 kDa molecular weight protein sharing 97% aa sequence identity with corresponding regions of mouse, 88% with human and bovine, 90% with feline and equine, and 89% with canine and porcine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells. Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity. Human VEGF165 binds the Semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2. VEGF is required during embryogenesis and functions to regulate the proliferation, migration, and survival of endothelial cells. In adults, VEGF functions mainly in wound healing and the female reproductive cycle. Pathologically, it is involved in tumor angiogenesis and vascular leakage. Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, Oncostatin M (OSM) and TNF-alpha.
Product Datasheets
Citations for Rat VEGF Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
24
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Sildenafil-Induced Revascularization of Rat Hindlimb Involves Arteriogenesis through PI3K/AKT and eNOS Activation
Authors: C Baron-Meng, A Bocquet, A Richard, AL Guihot, B Toutain, P Pacaud, C Fassot, G Loirand, D Henrion, L Loufrani
International Journal of Molecular Sciences, 2022;23(10):.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization -
Pigment Epithelium-Derived Factor (PEDF) Receptors Are Involved in Survival of Retinal Neurons
Authors: S Bürger, J Meng, A Zwanzig, M Beck, M Pankonin, P Wiedemann, W Eichler, JD Unterlauft
International Journal of Molecular Sciences, 2020;22(1):.
Species: Mouse
Sample Types: Whole Cells
Applications: Neutralization -
Cellular Mechanisms of Angiogenesis in Neonatal Rat Models of Retinal Neurodegeneration
Authors: D Asano, M Hokazono, S Hirano, A Morita, T Nakahara
Int J Mol Sci, 2019;20(19):.
Species: Rat
Sample Types: Whole Cells
Applications: ICC -
The effect of a single anti-Vascular Endothelial Growth Factor injection on neonatal growth and organ development: In-vivo study
Authors: S Khalili, Y Shifrin, J Pan, J Belik, K Mireskanda
Exp. Eye Res., 2018;169(0):54-59.
Species: Rat
Sample Types: In Vivo
Applications: In Vivo -
Myocardial infarction stabilization by cell-based expression of controlled Vascular Endothelial Growth Factor levels
Authors: L Melly, G Cerino, A Frobert, S Cook, MN Giraud, T Carrel, HT Tevaearai, F Eckstein, B Rondelet, A Marsano, A Banfi
J. Cell. Mol. Med., 2018;0(0):.
Species: Rat
Sample Types: Whole Tissue
Applications: IHC -
Bones in human CYP26B1 deficiency and rats with hypervitaminosis A phenocopy Vegfa overexpression
Authors: T Lind, R Lugano, AM Gustafson, M Norgård, A van Haerin, A Dimberg, H Melhus, SP Robertson, G Andersson
Bone Rep, 2018;9(0):27-36.
Species: Rat
Sample Types: Whole Tissue
Applications: IHC -
Genome-wide expression differences in anti-Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea
Authors: P Mirabelli, A Mukwaya, A Lennikov, M Xeroudaki, B Peebo, M Schaupper, N Lagali
Sci Rep, 2017;7(1):7616.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization -
Coronary angiogenic effect of long-term administration of Nigella sativa
Authors: LI Al Asoom
BMC Complement Altern Med, 2017;17(1):308.
Species: Rat
Sample Types: Whole Tissue
Applications: IHC -
Renal primordia activate kidney regenerative events in a rat model of progressive renal disease.
Authors: Imberti B, Corna D, Rizzo P, Xinaris C, Abbate M, Longaretti L, Cassis P, Benedetti V, Benigni A, Zoja C, Remuzzi G, Morigi M
PLoS ONE, 2015;10(3):e0120235.
Species: Rat
Sample Types: Whole Tissue
Applications: IHC -
FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy.
Authors: Deliyanti D, Zhang Y, Khong F, Berka D, Stapleton D, Kelly D, Wilkinson-Berka J
PLoS ONE, 2015;10(7):e0134392.
Species: Rat
Sample Types: Whole Tissue
Applications: IHC-P -
Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity.
Authors: Wang H, Yang Z, Jiang Y, Flannery J, Hammond S, Kafri T, Vemuri S, Jones B, Hartnett M
Invest Ophthalmol Vis Sci, 2014;55(2):737-44.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization -
The probiotic mixture VSL#3 accelerates gastric ulcer healing by stimulating vascular endothelial growth factor.
Authors: Dharmani P, De Simone C, Chadee K
PLoS ONE, 2013;8(3):e58671.
Species: Rat
Sample Types: Whole Tissue
Applications: Neutralization -
Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity.
Authors: McCloskey M, Wang H, Jiang Y, Smith G, Strange J, Hartnett M
Invest Ophthalmol Vis Sci, 2013;54(3):2020-6.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization -
Long-term gene therapy with thrombospondin 2 inhibits TGF-beta activation, inflammation and angiogenesis in chronic allograft nephropathy.
Authors: Daniel C, Vogelbacher R, Stief A, Grigo C, Hugo C
PLoS ONE, 2013;8(12):e83846.
Species: Rat
Sample Types: Whole Tissue
Applications: IHC -
Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.
Authors: Westenbrink BD, Ruifrok WP, Voors AA
Cardiovasc. Res., 2010;87(1):30-9.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization -
Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor.
Authors: Irani Y, Brereton HM, Tilton RG
Hybridoma (Larchmt), 2009;28(3):205-9.
Species: Human
Sample Types: Recombinant Protein
Applications: Binding Assay -
Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease.
Authors: Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL
Invest. Ophthalmol. Vis. Sci., 2008;49(7):3107-14.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization -
VEGF promotes vascular sympathetic innervation.
Authors: Marko SB, Damon DH
Am. J. Physiol. Heart Circ. Physiol., 2008;294(6):H2646-52.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization -
Heme oxygenase-1 promotes neovascularization in ischemic heart by coinduction of VEGF and SDF-1.
Authors: Lin HH, Chen YH, Chang PF, Lee YT, Yet SF, Chau LY
J. Mol. Cell. Cardiol., 2008;45(1):44-55.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization -
Effects of red wine polyphenols on postischemic neovascularization model in rats: low doses are proangiogenic, high doses anti-angiogenic.
Authors: Baron-Menguy C, Bocquet A, Guihot AL, Chappard D, Amiot MJ, Andriantsitohaina R, Loufrani L, Henrion D
FASEB J., 2007;21(13):3511-21.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization -
Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy.
Authors: Shimojo N, Jesmin S, Zaedi S, Otsuki T, Maeda S, Yamaguchi N, Aonuma K, Hattori Y, Miyauchi T
Am. J. Physiol. Heart Circ. Physiol., 2007;293(1):H474-81.
Species: Rat
Sample Types: Whole Cells
Applications: Neutralization -
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions.
Authors: Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Rakoczy PE, Gilbert RE
Proc. Natl. Acad. Sci. U.S.A., 2007;104(36):14448-53.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization -
Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1alpha accumulation and VEGF expression.
Authors: Yeh WL, Lu DY, Lin CJ, Liou HC, Fu WM
Mol. Pharmacol., 2007;72(2):440-9.
Species: Rat
Sample Types: Whole Cells
Applications: Neutralization -
Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia.
Authors: Yeh WL, Lin CJ, Fu WM
Mol. Pharmacol., 2007;73(1):170-7.
Species: Rat
Sample Types: Cell Culture Supernates
Applications: Neutralization
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsIsotype Controls
Reconstitution Buffers
Secondary Antibodies
Reviews for Rat VEGF Antibody
There are currently no reviews for this product. Be the first to review Rat VEGF Antibody and earn rewards!
Have you used Rat VEGF Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image